A preliminary trial of oral delta-9-tetrahydrocannabinol (THC) demonstrated an analgesic effect of the drug in patients experiencing cancer pain. Placebo and 5, 10, 15, and 20 mg THC were administered double blind to ten patients. Pain relief significantly superior to placebo was demonstrated at high dose levels (15 and 20 mg). At these levels, substantial sedation and mental clouding were reported.

Download full-text PDF

Source
http://dx.doi.org/10.1002/j.1552-4604.1975.tb02348.xDOI Listing

Publication Analysis

Top Keywords

analgesic delta-9-tetrahydrocannabinol
4
delta-9-tetrahydrocannabinol preliminary
4
preliminary trial
4
trial oral
4
oral delta-9-tetrahydrocannabinol
4
delta-9-tetrahydrocannabinol thc
4
thc demonstrated
4
demonstrated analgesic
4
analgesic drug
4
drug patients
4

Similar Publications

Exposure to Secondhand Cannabis Smoke Among Children.

JAMA Netw Open

January 2025

Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego.

Importance: The degree that in-home cannabis smoking can be detected in the urine of resident children is unclear.

Objective: Test association of in-home cannabis smoking with urinary cannabinoids in children living at home.

Design, Setting, And Participants: This cross-sectional study used baseline data from Project Fresh Air, a 2012-2016 randomized clinical trial to reduce fine particulate matter levels.

View Article and Find Full Text PDF

Background: Future breeding and selection of Cannabis sativa L. for both drug production and industrial purposes require a source of germplasm with wide genetic variation, such as that found in wild relatives and progenitors of highly cultivated plants. Limited directional selection and breeding have occurred in this crop, especially informed by molecular markers.

View Article and Find Full Text PDF

Prenatal cannabis use is associated with neurodevelopmental deficits, likely due to exposure to the psychoactive cannabinoid, (-)-Δ-tetrahydrocannabinol, and its active metabolite, (±)-11-OH-Δ-tetrahydrocannabinol. To determine causality, preclinical studies mimicking human fetal cannabinoid exposure must be conducted. Here we show cannabinoid concentrations across gestation in maternal plasma and paired fetal tissues in trimester 1 and 2 and maternal plasma and fetal umbilical venous plasma in trimester 3.

View Article and Find Full Text PDF

Cannabis is one of the most widely used drugs, and yet an understanding of its impact on the human brain and body is inconclusive. Medicinal and recreational use of cannabis has increased in the last decade with a concomitant increase in use by pregnant women. The major psychoactive compound in cannabis, Δ-tetrahydrocannabinol (THC), exists in different isomers, with the (-) trans isomer most common.

View Article and Find Full Text PDF

Cannabidiol (CBD) and Δ-tetrahydrocannabinol (THC), the main components of Cannabis sativa plants, can interact with specific cell receptors known as cannabinoid receptors (CBs). The endogenous compounds anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are CB agonists, and, alongside enzymes, they constitute the endocannabinoid system (ECS) and take part in neuromodulation. Several LC-MS/MS methods have been developed to quantify these compounds in biological matrixes, but a fast and simple method that can determine these analytes in plasma samples simultaneously is not available.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!